drugset / Trial / NCT06674915

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment

NCT06674915

Phase 1 Completed 24 enrolled Chengdu Suncadia Medicine Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study is being conducted to compare the pharmacokinetics, safety, and pharmacodynamics of HRS-5965 in subjects with mild to moderate hepatic impairment and normal hepatic function.

Timeline

Start
2024-11-26
Primary completion
2026-01-16
Completion
2026-01-16

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-5965 Small molecule 50 mg Oral

Indications